Keywords adverse drug reaction reporting systems, drug monitoring, drug-related side effects and adverse reactions, patients, pharmacovigilance AIMS Current trends in pharmacovigilance systems are veering towards patient involvement in spontaneous reporting of adverse drug reactions (ADRs). The aim of the current systematic review was to identify what is known and what remains unknown with respect to patient reporting to pharmacovigilance systems.
Introduction
Pharmacovigilance plays a key role in assessing, monitoring and preventing adverse drug reactions (ADRs) [1] . ADRs have a high clinical, social and economic cost as they can result in risk to life and having to stop taking an effective drug therapy, and a requirement for additional medical interventions and use of health services, with long hospitalizations [2] . Although randomized clinical trials are considered the gold standard for the evaluation of the efficacy and safety of drugs [3] , the design of such trials includes small and homogeneous populations monitored for short periods, making it difficult to detect many drug-related reactions [4] . Thus, the detection and reporting of suspected ADRs in clinical practice are the backbone of postmarket surveillance [5] . Current pharmacovigilance systems have been able to identify many major safety issues, even though their functions and methods leave considerable room for improvement [5] . These systems comprise, among other mechanisms, spontaneous reporting (SR) [6] . The main purpose of the SR system (SRS) is the early detection of new, rare and serious ADRs [7] and it has the advantage of covering the entire population in a cost-effective way [8] . The SRS has weaknesses, of which the most important is under-reporting; it has been estimated that only 6% of all ADRs are reported [9] . Under-reporting delays the detection and identification of safety problems, making it more difficult for health authorities to take action and preserve public health.
The formal inclusion of patients in SR is part of the present trend to foster a more proactive pharmacovigilance system [10] . Having more information available about ADRs through medicine users can possibly tackle under-reporting and identify new risks in a given subgroup of patients [8] . Although historically restricted to healthcare professionals (HCPs), recent years have brought a worldwide trend in allowing patients directly to report their accounts of ADRs to national pharmacovigilance authorities. Organizations such as the World Health Organization (WHO) and the European Union (EU) acknowledge the value of direct patient reporting [6] . In the EU, the pharmacovigilance system underwent a major reform in 2012. Among the major changes were the expansion of the definition of ADRs, the harmonization of several risk-based postmarketing surveillance methods and the introduction of the legal right for individual citizens to report suspected ADRs directly to the authorities [11, 12] . In the EU, there were 48 782 patient reports in 2015, representing an increase of 30% on 2014 [13] . In spite of these extensions to patient involvement in SR, the real benefits of incorporating patient reporting in pharmacovigilance systems are still being debated [12] . Some questions have been raised regarding the quality of documentation in patient reports, or the 'noise' that patients can produce when reporting already well-known ADRs [14] .
The aim of the present systematic review was to identify what is known and what remains to be discovered regarding the utility of patient reporting, and to summarize the views and opinions of patients as reporters. The review identified which aspects of the ADR information that patients provide are observational and which are subjective, and how this can be used to strengthen current pharmacovigilance systems.
Methods

Systematic literature search
A systematic literature search was conducted on the databases PubMed, CINAHL, Journals@Ovid and the Cochrane Library. The following combined text and medical subject headings (MeSH) terms were used: pharmacovigilance, direct patient report, patient adverse drug reaction reporting, consumer reporting and general public reporting. The complete search string used for the search was: ((adverse drug reaction OR adverse drug reactions OR side effect OR side effects OR adverse outcome OR adverse outcomes OR adverse event OR adverse events)) AND (patient OR patients OR consumer OR consumers OR general public)) AND (report OR reports OR spontaneous OR spontaneous report OR monitoring OR intensive monitoring OR direct report OR spontaneous reports)) AND (pharmacovigilance OR pharmacovigilance system).
The search was performed in January 2015, and was not limited to any type of study design or publication date ( Figure 1 ). The language for the search was limited to English. The studies were selected on the basis of their title and abstract. A manual search was also performed; the reference list of key articles identified during the selection process was searched manually to detect further eligible studies not previously found. To complement the information, an internet search was conducted using Google Scholar and the general search engine Google, using the same terms as used in the literature search in the electronic scientific databases.
Study selection and data abstraction
Studies were selected if they included: (i) reviews about patient reporting; (ii) an evaluation of patient reports in national or supranational official pharmacovigilance authorities; (iii) a comparison between patient and HCP reports submitted to pharmacovigilance authorities; and iv) surveys of patient experiences, opinions and awareness about reporting ADRs to pharmacovigilance authorities.
Patient reporting was defined as reports about adverse drug reactions submitted directly by patients or relatives to a pharmacovigilance authority, by means of passive or active surveillance methods. Exclusion criteria were as follows: studies in which patients or the public reported to pharmaceutical companies, patient organizations or another authority not related to pharmacovigilance; cases where patients reported ADRs to a hospital for purposes other than reporting to a pharmacovigilance authority; or general public surveys. Abstracts without full-text studies were excluded. There was no limitation on whether the study concerned only one specific drug or pharmaceutical formulation, such as a vaccine.
In short, the following 'PICO' was applied in the present study: Patients (people taking any form of medication, or their relatives); Intervention (patients or relatives reporting to a pharmacovigilance authority); Comparison (comparison with HCPs); and Outcomes (new information; new ADRs; type of reaction reported).
An electronic matrix was developed in Microsoft Excel prior to the full-text review, with predetermined characteristics. The articles were assessed independently by two reviewers (P.I. and M.A.) based on their titles and abstracts, according to the inclusion and exclusion criteria. Studies that fulfilled the inclusion criteria were retrieved for full assessment. The articles were then read carefully, and checked for Figure 1 Flow diagram of study selection
The value of patient reporting to the pharmacovigilance system content. A full-text analysis of the articles was made, and the information was condensed according to categories into an Excel file. This was done by one reviewer (P.I.). While conducting the full-text analysis, the information presented in Table 1 was extracted, with a description of study characteristics, methods and key findings. After conducting the analysis, the results on the advantages and limitations/drawbacks brought by patient reporting were organized in Table 2 , and a summary of the contributions to pharmacovigilance through patient reporting emerging from the studies was extracted into Table 3 . Disagreements were resolved through discussion and consensus. The tables were reviewed by the other researchers (A.C. and M.A.) for accuracy and completeness. Disagreements were solved by consensus.
Quality assessment
The process of conducting the systematic review followed the steps recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist [15] . Two authors (P.I. and M.A.) read and carefully assessed each retrieved study. The methodological quality of the studies was assessed according to principles of Grading of Recommendations, Assessment, Development and Evaluations (GRADE), and the studies were organized to four categories on the basis of the methodology applied (reviews, observational studies, surveys, other study designs). Due to a lack of homogeneity among the studies, a meta-analysis of the data was not possible, but a qualitative analysis was conducted. This systematic review of published studies did not require ethics approval.
Results
Of the identified 721 studies, 34 full-text studies were included in the qualitative analysis ( Figure 1 ). The identification, screening and evaluation of eligibility of articles for final inclusion are presented in Figure 1 .
Of the identified 34 studies, 5 were literature reviews, 14 observational studies and 8 surveys, and 6 studies applied mixed methods (Table 1) . Most of the studies (30 out of 34) came from European countries, particularly the Netherlands (n = 15), United Kingdom (UK) (n = 10) and Denmark (n = 5).
Summary of evidence on advantages and limitations of patient reporting
Combining the evidence on the advantages and limitations of direct patient reporting, it was shown that patients report different ADRs when compared with HCPs, and identify novel ADRs [16] [17] [18] [19] [20] (Table 2) . Patients provide new insights into ADRs by bringing information on different body systems affected by medicines, such as the central nervous system [16, 17, 19] (Table 3) . Patients can be very important in identifying ADRs in specific populations, or types of medicine [17, [21] [22] [23] . The information provided by patient reports can be significant for ADR signal detection [24, 25] . One important characteristic of patient reports is the subjective description of ADRs.
Some of the barriers were also identified. Despite the fact that many countries allow patient reporting to take place, the reporting rate and awareness are still low [26] . It was pointed out that awareness should be raised so that patients can become more engaged [26] . The new information provided by patients seemed to be valuable and of high quality [27] . None of the studies provided insight on what is being done to increase participation and awareness.
Descriptive findings from the studies Reviews. The search strategy identified five reviews [19, [28] [29] [30] [31] , of which two were systematic reviews [19, 30] . The studies synthesized data to identify the evidence on the potential of direct patient reporting [28] [29] [30] [31] , and to compare the differences between patient and HCP reports [19, 30] . All the reviews concluded that patient reporting was valuable, with the differences between patient and HCP reports adding to the knowledge about ADRs [19, [29] [30] [31] . Most of the reviews (three out of five) stated the need for further evidence on the benefits and drawbacks of patient reporting [19, 29, 30] . As the reviews were published between 2006 and 2015, they included data from different periods and different countries, reflecting the different maturation states of patient involvement in ADR reporting [19, [28] [29] [30] .
Observational studies. All of the 14 observational studies [16-18, 20-23, 25, 27, 33-37] were retrospective, and most commonly (8 out of 14 studies) had the aim of comparing patient and HCP ADR reports [16-18, 20, 25, 27, 33, 35] . There were five studies from Denmark [17, [20] [21] [22] [23] , five from the Netherlands [16, 27, 32, 33, 35] , two from the UK [18, 25] , one from France [34] and one from China [36] . Two of the Danish studies focused on analysing the Danish experience with patient ADR reporting [17, 20] , and three studies performed an analysis of the ADRs presented in the European ADR database EudraVigilance [21] [22] [23] . The majority of the studies coming from the Netherlands [35] and the UK [18, 25] compared the differences between ADR reports from patients and HCPs. Two studies were concerned with media exposition of statins [32, 33] , and one with the patient contribution to ADR signal detection [25] . Both UK studies analyzed the UKs national pharmacovigilance database but looked at different outcomes [18, 25] .
Overall, these studies found that patient reporting is valuable, with no major qualitative differences between patient and HCP reports [20, 34] . Patients provided welldocumented, consistent information [17, 43] , reporting different categories of ADRs for different types of medicines when compared with HCPs. Patients provided more consistent information, a greater number of categories of ADRs and a greater range of medicines [16, 17, 20, 22, 23, 25, 34] . This contribution can provide a positive, complementary input to that of HCPs for safety signal generation [25] . Patients were found to report more often than HCPs on the impact of ADRs on daily life, making a more detailed description of reactions [27] . A common feature of almost all of the studies from Denmark was the identification that most of the ADRs reported by patients related to central nervous system medication [17, 20, 22, 23] . Four out of The value of patient reporting to the pharmacovigilance system The value of patient reporting to the pharmacovigilance system The value of patient reporting to the pharmacovigilance system The value of patient reporting to the pharmacovigilance system the 14 studies referred to the need for further research to clarify the value and characteristics of patient reporting [18, 22, 34, 36] . Some of the studies found differences between patient and HCP reporting [18, 32, 33, 35, 36] . For example, UK patients seemed to report more ADRs with a lesser degree of severity [18] . In a study from the Netherlands, differences were found in the level of participation of the population in a web-based intensive monitoring programme, which might have led to an underestimation of ADRs [35] . A study from China investigated ADRs in a paediatric population, concluding that patients are more likely than HCP to report new ADRs, although patient participation was low [36] . Two studies from the Netherlands focused on the impact of media exposition on the reporting of ADRs for a specific class of drugs (statins) [32, 33] . In general, media attention led to a peak in patient reports received by the pharmacovigilance authority, without affecting the overall reporting rate by patients.
Surveys. Eight of the identified studies were surveys, carried out using different methods, such as web-based [26, 38] or postal [38, 39] questionnaires, and group [40, 41] or personal [38, 39, 42, 43] interviews. Six studies were from either the Netherlands [37, 41, 42] or the UK [38] [39] [40] . Most of the studies from the UK [38] [39] [40] and one from the Netherlands [37] provided an overview of patients views and experiences with ADR reporting. These studies showed that patients consider the severity of the ADR and the need to share experiences, such as the impact of ADRs on their daily life, as the main motives to report [37, 41] (Table 3) . Patients perceived the possibility of reporting ADRs directly as important [38] , and were able to identify ADRs in a manner that mirrored HCPs [39] . Overall, patients views were positive [38, 41, 43] . However, studies identified a need to empower people to report, and provide feedback on their reports [40, 43] .
Two studies, one from the Netherlands [42] and the other from France [26] , aimed to study the countries in which patient reporting was available. It was found to be available in 44 countries worldwide in 2012 [26] . Although there were some differences in the way that different countries dealt with these reports, patient reporting was recognized as valuable [26, 42] . The availability of the reporting form online seemed to increase the reporting rate [26] . However, the content of the form was different for different countries, and should be harmonized [26] .
Mixed methods. Almost all of the studies [24, 29, [44] [45] [46] [47] [48] , were from the Netherlands [44] [45] [46] [47] [48] . They explored the value of a web-based intensive monitoring system using patients as an information source. These studies focused on specific drugs, such as pregabalin [44, 46] and duloxetine [47] . The studies concluded that this type of intensive monitoring can gain insight about the daily use of the medicine and its safety profile [44, [46] [47] [48] . It can generate other types of information when compared with SR, and provide more information about reactions, including the quantification of latency [44, 46, 48] . One of the Dutch studies focused on the contribution that patient reports provide to ADR signal generation [24] . It concluded that patients provide a valuable and considerable contribution to the detection of This study aggregates several other studies.
Table 2
Evidence on the advantages and limitations of patient reporting identified from the studies included in the systematic review (n = 34) [17, 18, 21-23, 25, 27, 29-34, 36, 45-48] • Information is accumulated in a faster way
• Complements information from HCPs
• SR is not the only method to collect information • Lack of further studies concerning other methods • New information is not superfluous or of low quality; however, the volume is still low
Patients report different
ADRs when compared with HCPs 15 [16-20, 25-27, 29-33, 36] • Patients report ADRs affecting different body systems
• Nervous system disorders, general disorders and administration site disorders are the biggest groups
• Limited information yet • Level of detail that patients provide needs to be better assessed
Patients identify new ADRs 11 [16-18, 20, 24, 25, 29, 31, 32, 36] • Patients provide more detailed information • Makes the system more robust
• Awareness must be raised so that patients can become more engaged
Patients report the impact of ADRs in daily life 11 [27, 29, 31-33, 37, 40, 41, 43, 48] • Patients report more subjective factors safety signals, in addition to that of HCPs [24] . This has also been corroborated in another study [47] . A UK study aimed to provide a general evaluation of the impact of patient reporting on the UK pharmacovigilance system. It concluded that patient reporting has the potential to add value to the pharmacovigilance system by providing reports with novel information about different types of drug and ADRs, thus complementing HCP reports and generating new safety signals. Reports by patients were found to describe ADRs in sufficient detail [29] .
Discussion
The evidence gathered in the present systematic review confirmed the view that patient reporting makes a positive contribution to the general knowledge about ADRs. Most of the studies showed this, although in a general way. Thus, there was a lack of evidence on any of the possible drawbacks of patient reporting. These include the identification and accuracy of reported symptoms, the seriousness of the reactions and costs to the system [11, 49] . No study elaborated on the [16, 17, 19, 29] . This also applied to the evidence on the clinical value of ADRs identified by patients. There was limited information about the type of reactions that patients identify in other countries, both in Europe and in the rest of the world. There was a lack of data coming from such countries as the USA and Australia, or from the WHO Uppsala Monitoring Centre, representing various countries from different continents. Further research is needed to improve our understanding of the value of, and problems in, patient reporting to pharmacovigilance authorities. The present review gathered evidence that patients add new clinical and subjective information on ADRs [19, 28, 40] . Patient reports are not meant to replace the reports coming from HCPs, but to provide an additional source of information [7] . Patients report different ADRs and medicines when compared with HCPs [21] [22] [23] . Reports coming from patients have also allowed for the identification of new ADRs, and led to the strengthening of safety signals [18, 25] . This contribution is considered important by pharmacovigilance authorities as they allow for a faster accumulation of knowledge about ADRs [42] .
An important aspect of patient reports is that they describe the ADRs with more detail and subjective factors than HCPs [27, 32] . Patients can provide first-hand information about medicine use and experiences, such as the way an ADR affects their daily lives [38, 40] . However, the studies did not provide data about the number of patient reports that need to be followed up, in order to be confirmed medically. Although all such reports are treated in the same way in the EU [50] , there is scant information about how the rest of the world treats patient reports. HCP reports are often incomplete and the quality of the language can be a barrier in the description of the ADR [7, 51] . The quality of the reports should be researched further to evaluate the input provided by patients, especially in special groups with a strong drug therapy burden.
Despite the possibility of patient reporting increasing worldwide [26] , awareness is still low [26] . The UK has had patient involvement in SR since 2005, but only 8.5% of patients are aware of the possibility of reporting [29] . The length of time since the introduction of direct patient reporting seems to play a part in this -e.g. the countries that introduced patient reporting earlier, such as the Netherlands, Denmark and the UK, have a higher reporting rate [16, 17, 29] . By contrast, countries such as Portugal, Malta and Hungary, which introduced this facility more recently, show low levels of patient reporting [19, 26] . Although not the aim of the present review, it is not clear how HCP reporting is evolving in the countries that have introduced patient reporting. Raising patient and HCP awareness of ADR reporting should be treated as a priority by national regulatory agencies, especially in countries with a low reporting rate. Patients who report have different characteristics to those who do not [35, 38] ; therefore, further research should focus on identifying the characteristics of patient reporters, in particular the psychological aspects that help to explain the desire to participate.
Existing pharmacovigilance systems have proven to be useful in identifying patient safety issues, although there is scope for optimizing and improving. SR has known limitations on data collection and reporting. The inclusion of an active form of vigilance seems to play an important role. Web-based sources are becoming increasingly important, and this method can collect more information about certain drugs [53] . The fact that this form of stimulated reporting targets specific drugs or patient populations can play a role in providing more safety data in a shorter period of time. However, only the Netherlands has experience of this type of reporting. The majority of studies have shown that patients provide mostly confirmatory information on the safety profile of drugs [17, 19] . Further research on this topic is needed.
The drug regulatory pathway is evolving, adding more transparency in its decision-making process and taking into account the voice of patients [14] . There is also a growing interest in whether social media can capture patientgenerated safety information. The present review did not identify any studies that provided social media-generated safety surveillance information. This type of tool could play a role in pharmacovigilance in the future [53, 54] .
Strengths and limitations
The present systematic review collected an updated and comprehensive set of information about the direct patient reporting of ADRs. One of the strengths of the studies included was that they summarized current evidence on the contribution of patient reporting in different settings and countries, as well as patients' opinions and views. The range of existing studies indicated that there are several gaps in knowledge related to patient reporting. Limitations to the study included the heterogeneity of methods used in the published studies, hindering comparisons between them. This poses challenges when examining studies, practices and countries. Another limitation was the geographical origin of the articles, as most came from only three countries in Europe.
The review analysed only published studies concerning patient reports to pharmacovigilance authorities. Although there is extensive literature on patients reporting in hospital settings or to consumer organizations, the use of this information remains limited. The inclusion of information submitted only to pharmacovigilance authorities allowed us to make comparisons with HCP-reported ADRs. The review did not include any unpublished data, such as abstracts without the full text, to avoid the inclusion of incomplete data or methodological issues with the selected studies.
Conclusions
Patient reports add new information and perspective about ADRs in a way otherwise unavailable. This new information can lead to the strengthening of safety signals and increase the knowledge about ADRs. There are differences between patient and HCP reports. This is seen as positive, as the information provided by patients complements that coming from HCPs. The subjective information that patients bring to the system can be used to strengthen the current pharmacovigilance system with more evidence about the impact of ADRs on patientsdaily lives. However, the present review identified gaps in knowledge that should be addressed in future research in order to understand better the full potential and problems of patient reporting.
